|
|
|
|
|
|
|
||||
| Home Help Feedback Subscriptions Archive Search Table of Contents | ||||
|
Fig. 5. Downregulation of Ras-dva functioning by the anti-Ras-dva morpholino or
Ras-dva dominant-negative mutant, DN-Ras-dvaT22N, leads to an inhibition of
anterior ectoderm markers expression. (A,B) The expression of the
neural crest markers Sox9 and Slug is inhibited on the side
of embryos microinjected with DN-Ras-dvaT22N mRNA. (C) By
contrast, the microinjection of DN-Ras-dvaT22N mRNA resulted in a
broadening of the expression domain of the neural border marker Msx1.
(D) No effect on the expression of posterior neural marker
HoxB9 was observed on the side microinjected with
DN-Ras-dvaT22N mRNA. (E-J) The expression of markers of the
neural plate (G, Otx2; H, Pax6), the anterior neural ridge
(E, BF-1), the cranial placodes (G, Otx2;H, Pax6;
F, Xag2) and the neural crest (J, Slug; I, Sox9) is
inhibited on the side of embryos microinjected with the anti-Ras-dva
morpholino. (K,L) Rescue of anti-Ras-dvaMO effects by co-injection of
synthetic Ras-dva mRNA. The inhibited expression of the Slug
marker, caused by a break of endogenous Ras-dva mRNA translation (K),
can be restored by co-injection of a synthetic Ras-dva construct
lacking the MO binding site (L). This result confirms the specificity of
anti-Ras-dva MO effects. All embryos are shown from the anterior, dorsal side
upwards. The `primed' counterpart pictures show the location of progenies of
the microinjected blastomeres labeled by FLD tracer.
|
